TerminatedPhase 2NCT01676311
Effects of Huperzine A in Treatment of Moderate to Severe TBI
Studying Moderate and severe traumatic brain injury
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Spaulding Rehabilitation Hospital
- Principal Investigator
- Ross Zafonte, DOSpaulding Rehabilitation Hospital
- Intervention
- Huperzine A(drug)
- Enrollment
- 14 target
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2013 – 2018
Study locations (1)
- Spaulding Rehabilitation Hospital, Charlestown, Massachusetts, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01676311 on ClinicalTrials.govOther trials for Moderate and severe traumatic brain injury
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT06866691Seizure Prevention in Traumatic Brain Injury With Levetiracetam and LacosamideWake Forest University Health Sciences
- RECRUITINGNANCT06241482Safety and Efficacy of Enhanced Recovery After Surgery in Neurocritical CareShanghai 6th People's Hospital
- RECRUITINGPHASE1, PHASE2NCT06282965Safety and Efficacy of Angiotensin (1-7) in Persons With Moderate to Severe Traumatic Brain InjuryUniversity of Arizona
- RECRUITINGPHASE1NCT05716048Combinatory Rehabilitation Used for Substantially Helping Individuals With Traumatic Brain InjuryKessler Foundation
- ACTIVE NOT RECRUITINGNANCT05636020Intervention to Change Affect Recognition and EmpathyIndiana University
See all trials for Moderate and severe traumatic brain injury →